Tumor inhibition in xenograft model of diffuse intrinsic pontine glioma via ultra-low and low-frequency magnetic field therapy.

A low-frequency (DC-22.05 kHz), time-varying magnetic field signal (rfe_A1A) was tested against the human-derived SF8628 cell line, a diffuse intrinsic pontine glioma (DIPG). This study was done to determine the efficacy and mechanism of action of the rfe_A1A signal, in vitro and in vivo. In vitro, an acellular tubulin polymerization assay and an SF8628 cell culture assay increased tubulin polymerization rates and reduced cell division, respectively. Mouse survival models of DIPG, subsequently exposed to the rfe_A1A signal, demonstrated significantly longer survival times and biomarker changes in Ki67 expression, consistent with a slowdown in cell-division rates. The rfe_A1A signal significantly increased survival time in a DIPG model, a novel strategy tested in clinical studies and compassionate use cases.